Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: Risk of neoplastic progression in Barrett's esophagus

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2387-2395

  Siahpush, Sid H ^a,b   Vaughan, Thomas L ^a,b   Lampe, Johanna N ^a   Freeman, Robert ^a   Lewis, Skay ^a   Odze, Robert D ^d   Blount, Patricia L ^a,b   Ayub, Kamran ^c   Rabinovitch, Peter S ^a,b   Reid, Brian J ^a,b   Chen, Chu ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRINUCLEOTIDE;

ADULT; ALLELE; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TETRAPLOIDY; TRINUCLEOTIDE REPEAT;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLOIDIES; POLYMORPHISM, GENETIC; RECEPTOR, IGF TYPE 1;

EID: 38849182655     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0986     Document Type: Article

References (64)

1. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in White males. Cancer 2001;92:549-55.
2. Kubo A, Corley DA. Marked regional variation in adenocarcinomas ofthe esophagus and the gastric cardia in the United States. Cancer 2002;95:2096-102.
3. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
4. Morales TG, Sampliner RE. Barrett's esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999;159:1411-6.
5. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
6. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
7. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
8. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
9. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-3.
10. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
11. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
12. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
13. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
14. Cameron AJ. Epidemiologic studies and the development of Barrett 's esophagus. Endoscopy 1993;25:635-6.
15. Vaughan T. The esophagus. In: EL Franco, TW Rohan, editors. Cancer precursorss: epidemiology, detection and prevention. 2002. p. 96-116.
16. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects ofin sulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
17. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-12.
18. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
19. Harman SM, Metter EJ, Blackman MR, et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
20. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
21. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995;270:13589-92.
22. Kaaks R, Rinaldi S, Lukanova A, et al. Correspondence re: Giovannucci et al., A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9: 345-9.
23. Cancer Epidemiol Biomarkers Prev 2001;10:1103-4.
24. Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, et al. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 2005;14:48-52.
25. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002;63:317-32.
26. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
27. Jernstrom H, Sandberg T, Bageman E, Borg A, Olsson H. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 2005;92:857-66.
28. Wong HL, Delellis K, Probst-Hensch N, et al. A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev 2005;14:144-51.
29. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 2005;14:1394-401.
30. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1204-11.
31. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299-307.
32. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor- binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
33. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP-3: Influence on serum levels of insulin -like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.
34. Zhang ZW, Newcomb PV, Moorghen M, et al. Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom). Cancer Causes Control 2004;15:211-8.
35. Wang L, Habuchi T, Tsuchiya N, et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407-11.
36. Li L, Cicek MS, Casey G, Witte JS. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:497-8.
37. Slattery ML, Samowitz W, Curtin K, et al. Associations among IRS1, IRS2, IGF1, and IGFBP-3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1206-14.
38. Meloni R, Fougerousse F, Roudaut C, Beckmann JS. Trinucleotide repeat polymorphism at the human insulin-like growth factor I receptor gene (IGF1R). Nucleic Acids Res 1992;20:1427.
39. Poduslo SE, Dean M, Kolch U, O'Brien SJ. Detecting high-resolution polymorphisms in human coding loci by combining PCR and single-strand conformation polymorphism (SSCP) analysis. Am J Hum Genet 1991;49:106-11.
40. Rudolph RE, Vaughan TL, Kristal AR, et al. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. JNCI Cancer Spectrum 2003;95:750-7.
41. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
42. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
43. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
44. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
45. Chiano MN, Clayton DG. Genotypic relative risks under ordered restriction. Genet Epidemiol 1998;15:135-46.
46. Chen SC, Chou CK, Wong FH, Chang CM, Hu CP. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991;51:1898-903.
47. Liu YC, Leu CM, Wong FH, et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002;9:665-74.
48. Takaoka M, Harada H, Andl CD, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004;64:7711-23.
49. Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 1999;8:1265-72.
50. Giovannucci E, Haiman CA, Platz EA, et al. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2002;11:1509-10.
51. Schildkraut JM, Demark-Wahnefried W, Wenham RM, et al. IGF1 (CA)19 repeat and IGFBP-3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 2005;14:403-8.
52. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002;11:319-20.
53. Kato I, Eastham J, Li B, Smith M, Yu H. Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003;18:203-9.
54. Vinayek R, Pichney LS, Tantry U, et al. Characterization of insulin-like growth factor I receptors in human esophageal epithelial cells. Am J Physiol 1994;267:G105-14.
55. Peters G, Gongoll S, Langner C, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 2003;443:139-45.
56. Schips L, Zigeuner R, Ratschek M, et al. Analysis of insulin -like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol 2004;122:931-7.
57. Cardillo MR, Monti S, Di Silverio F, et al. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003;23:3825-35.
58. Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211-22.
59. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-36.
60. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Human Pathology 2003;34:803-8.
61. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566-73.
62. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
63. Ito Y, Nakachi K, Imai K, et al. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor β, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 2005;15 Suppl 1:S67-73.
64. Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N. Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 2002;48:2248-51.